[Media Releases] LegoChem, Longthera and Medicilon Form Collaboration to Co-develop LegoChem's New Antibiotic LCB01-0699 (Medicilon, 29 Nov 2013)
Title: LegoChem, Longthera and Medicilon Form Collaboration to Co-develop LegoChem's New Antibiotic LCB01-0699 Publication: Medicilon website Date: 29 Nov 2013 URL: link to website
LegoChem and Longthera today announced that they have entered into a collaboration agreement to co-develop LegoChem’s LCB01-0699, a novel antibiotic small molecule against linezolid resistant strains.
About LegoChem Biosciences
LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC). |